疑难病杂志2024，Vol.23Issue(5)：635-640,6.DOI:10.3969/j.issn.1671-6450.2024.05.026
中重度活动性Graves眼病药物治疗新进展
Progress in drug therapy for moderate to severe active Graves ophthalmopathy
摘要
Abstract
Graves ophthalmopathy(GO)is an extrathyroidal manifestation of Graves'disease,mainly a complexau-toimmune disease mediated by cellular immunity.Orbital fibroblasts and adipocytes are target cells for immune response,while Thyroid stimulating hormone receptor and insulin-like growth factor-1 are key autoantigens.In addition to smoking,post radiation iodine therapy,and other risk factors,hypercholesterolemia has been identified as a new risk factor for GO.Corticosteroids have an unshakable position in the treatment of moderate to severe active GO,but some patients do not re-spond after treatment or experience recurrence.It is necessary to seek new drugs.Bio-targeted agents,cytokine inhibitors,and statins with anti-inflammatory effects have gradually been studied and applied in the clinical treatment of GO.This re-view mainly introduces the main pathogenesis of GO and the new progress in drug therapy for moderate to severe active GO.关键词
Graves眼病/糖皮质激素/免疫抑制剂/生物靶向制剂/治疗Key words
Graves ophthalmopathy/Glucocorticoids/Immunosuppressants/Bio-targeted formulations/Treatment分类
医药卫生引用本文复制引用
王璇璐,彭年春,胡颖..中重度活动性Graves眼病药物治疗新进展[J].疑难病杂志,2024,23(5):635-640,6.基金项目
2022 年度贵州省卫生健康委科学技术基金项目(gzwkj-2022-001) （gzwkj-2022-001）
2021 年贵州医科大学附属医院博士科研启动基金项目(gyfybskt-2021-11) Science and Technology Fund Project of Guizhou Provincial Health Commission In 2022(gzwkj-2022-001) （gyfybskt-2021-11）
Doctoral Research Start-up Fund of Affiliated Hospital of Guizhou Medical University in 2021(gyfybskt-2021-11) （gyfybskt-2021-11）
